In Vitro Antiviral Activity of Cabotegravir against HIV-2

Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01299-18. doi: 10.1128/AAC.01299-18. Print 2018 Oct.


We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC50s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.

Keywords: HIV-2; PrEP; West Africa; antiretroviral therapy; cabotegravir; human immunodeficiency virus; treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • HIV-1 / drug effects
  • HIV-2 / drug effects*
  • Pyridones / pharmacology*


  • Anti-HIV Agents
  • Pyridones
  • cabotegravir